How can sponsors, CROs, and sites adapt to improve enrollment and retention in a changing clinical trial environment?
The Partnerships with Sites Summit challenges how sponsors, CROs, and sites adapt to a rapidly evolving clinical trial ecosystem shaped by shifts in the global site landscape, increasing study complexity, evolving technology, and changing operating models. These forces are reshaping clinical trial execution and placing new demands on consistency, coordination, and performance across the system.
As the role of sites continues to evolve, the summit brings stakeholders together to rethink how trials are designed and executed in this new environment—where execution determines enrollment and retention outcomes.
The summit focuses on the key forces shaping this inflection point:
- Increasing variability across site types is challenging consistent trial execution
- Rising protocol complexity and operational demands are straining coordination and site capacity
- Fragmented technology adoption is creating workflow inefficiencies across studies and systems
- Misaligned operating models are driving variability in startup timelines, delivery, and performance outcomes
- Earlier alignment on study design, governance, and execution expectations is becoming critical to improving feasibility and consistency
OPENING KEYNOTE
The Global Shift in Clinical Trial Sites: What the Data Reveals and What It Means for You
New data from Tufts CSDD reveals dramatic changes in the global investigative site landscape. This session presents evidence of these structural shifts and examines their implications for sites, sponsors, CROs, and academic research centers, including potential market and regulatory responses as the industry adapts to an evolving global landscape.
Kenneth Getz, MBA,
Executive Director and Professor, Tufts Center for the Study of Drug Development
Tufts University School of Medicine
